"Velesco’s fees are competitive…, they deliver an excellent product at a good value"

"Velesco stands out with a flexibility and responsiveness that complements their scientific expertise"

"Velesco is doing a great job; I'm pleased with how rapidly they are addressing our needs."

"Timely response and commitment to partnership…for Velesco, it’s there."

"The Velesco team really functioned as an extension of our in house team..."

Analytical Method Development: Expert method development, validation, and troubleshooting >

Drug Formulation:Early stage, knowledge based formulation development >

GMP Clinical Supplies:Softgel capsules, non-sterile liquids, solids, etc..>

Pharmaceutical Consulting:Thoughtful consulting from our experience on your side of the desk >

Drug Formulation Challenge 4

Injectable Formulation Developed for a Low Solubility Compound at a High Dose

Our client had a poorly soluble, non-ionizable compound and required a high dose injectable formulation for animal studies.

Velesco solution:

Regular solvent mixtures were unable to achieve the required dose, but the precipitation characteristics suggested nucleation inhibitors might work.
A successful non-toxic drug formulation containing anti-nucleation polymers was developed.

Back to drug formulation development case studies

News and Events

Pace® Life Sciences Acquires Velesco Pharmaceutical Services, Expanding Capabilities in Drug Development Services

Read the Press Release!

Dave Barnes, Ph.D. CEO/CSO is a featured speaker for the webinar Topical Formulation: Selection of Excipients and Better Process Understanding for Success in Commercial Manufacturing. Webinar recording available now.

View Recording!

Newly Acquired DEA Analytical Laboratory License. We are licensed to use schedules 2, 2N, 3, 3N, 4, and 5.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Gerry Cox, Founder and Chief Operating Officer at Velesco Pharmaceutical Services.

Roundtable: M&A trends in CDMO - Molecule to Market

New Velesco Pharma clinical manufacturing facility begins operations.

Read the press release here.

Lisa Crandall, MS, and Peter Angus, PhD, spoke with Pharmaceutical Technology about the best practices in stability testing.

Read the interview here.

Velesco has expanded our analytical facilities in a new Wixom, Michigan location with the help of the Bank of Ann Arbor Technology Industry Group.

Read the press release here.

CEO Dave Barnes has been published in a new Pharmoutsourcing article on Clinical Trial Materials and Manufacturing!

1 new job postings! Careers